| scholarly article | Q13442814 |
| P2093 | author name string | Su-Jin Kim | |
| Christopher H S McIntosh | |||
| Cuilan Nian | |||
| Doris J Doudet | |||
| P2860 | cites work | The small GTP-binding protein rac regulates growth factor-induced membrane ruffling | Q27861063 |
| A novel mechanism for the suppression of a voltage-gated potassium channel by glucose-dependent insulinotropic polypeptide: protein kinase A-dependent endocytosis | Q27863888 | ||
| Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum | Q28117412 | ||
| Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen | Q28141785 | ||
| Synaptopodin orchestrates actin organization and cell motility via regulation of RhoA signalling | Q28235253 | ||
| Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM | Q28303637 | ||
| Glucose-dependent insulinotropic polypeptide-mediated up-regulation of beta-cell antiapoptotic Bcl-2 gene expression is coordinated by cyclic AMP (cAMP) response element binding protein (CREB) and cAMP-responsive CREB coactivator 2 | Q28572231 | ||
| Spatial regulation of the cAMP-dependent protein kinase during chemotactic cell migration | Q30476244 | ||
| MHC class II deprivation impairs CD4 T cell motility and responsiveness to antigen-bearing dendritic cells in vivo | Q30479335 | ||
| A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography | Q30647460 | ||
| [Ser2]- and [SerP2] incretin analogs: comparison of dipeptidyl peptidase IV resistance and biological activities in vitro and in vivo | Q33194892 | ||
| Five-year follow-up after clinical islet transplantation | Q33218078 | ||
| A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice | Q33268721 | ||
| CD26, let it cut or cut it down. | Q33702158 | ||
| Rho-family GTPases: it's not only Rac and Rho (and I like it). | Q34305856 | ||
| Islet transplant: an option for childhood diabetes? | Q35159274 | ||
| The role of gut hormones in glucose homeostasis | Q35251016 | ||
| Small-molecule agonists for the glucagon-like peptide 1 receptor | Q35612392 | ||
| Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system | Q35714885 | ||
| Clinical islet transplantation: advances and immunological challenges | Q35730793 | ||
| Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans. | Q36075992 | ||
| Exendin-4 modulates diabetes onset in nonobese diabetic mice | Q36509803 | ||
| Performance measurement of the microPET focus 120 scanner | Q38504765 | ||
| Glucose-dependent insulinotropic polypeptide (GIP) stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and dow | Q40437409 | ||
| Use of recombinant adenovirus for metabolic engineering of mammalian cells. | Q40571045 | ||
| Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. | Q40637074 | ||
| Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. | Q40667988 | ||
| Quantification of target gene expression by imaging reporter gene expression in living animals. | Q41753201 | ||
| Protein kinase A regulates Rac and is required for the growth factor-stimulated migration of carcinoma cells | Q43770508 | ||
| Soluble CD26/dipeptidyl peptidase IV enhances transendothelial migration via its interaction with mannose 6-phosphate/insulin-like growth factor II receptor | Q44079524 | ||
| Dipeptidyl peptidase IV inhibition in animal models of diabetes. | Q44390028 | ||
| Glucose-dependent insulinotropic polypeptide (GIP): development of DP IV-resistant analogues with therapeutic potential. | Q44390031 | ||
| Acceleration of diabetes in young NOD mice with a CD4+ islet-specific T cell clone | Q44534362 | ||
| Characterisation of human dipeptidyl peptidase IV expressed in Pichia pastoris. A structural and mechanistic comparison between the recombinant human and the purified porcine enzyme. | Q44726066 | ||
| Rapid and reproducible radiosynthesis of [18F] FHBG. | Q44740911 | ||
| (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes | Q45212807 | ||
| Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes | Q46654955 | ||
| Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice | Q46734172 | ||
| Quantitative micro positron emission tomography (PET) imaging for the in vivo determination of pancreatic islet graft survival | Q48922892 | ||
| Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes | Q51484798 | ||
| Continuous stimulation of human glucagon-like peptide-1 (7-36) amide in a mouse model (NOD) delays onset of autoimmune type 1 diabetes | Q51746108 | ||
| Epinephrine regulation of the endothelial nitric-oxide synthase: roles of RAC1 and beta3-adrenergic receptors in endothelial NO signaling | Q53527970 | ||
| Ischemia/Reperfusion Injury: The Role of CD26/Dipeptidyl-Peptidase-IV-Inhibition in Lung Transplantation | Q58864265 | ||
| Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV | Q71940328 | ||
| CD26/DPP IV in experimental and clinical organ transplantation | Q73214416 | ||
| Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients | Q73398743 | ||
| Islet filtration: a simple and rapid new purification procedure that avoids ficoll and improves islet mass and function | Q78330004 | ||
| GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress | Q79329446 | ||
| Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells | Q80731025 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 641-651 | |
| P577 | publication date | 2008-12-10 | |
| P1433 | published in | Diabetes | Q895262 |
| P1476 | title | Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation | |
| P478 | volume | 58 |
| Q35055522 | Activation of the GLP-1 receptor signalling pathway: a relevant strategy to repair a deficient beta-cell mass |
| Q50994089 | Altered Proportions of Naïve, Central Memory and Terminally Differentiated Central Memory Subsets among CD4+ and CD8+ T Cells Expressing CD26 in Patients with Type 1 Diabetes |
| Q26749089 | An Update on the Effect of Incretin-Based Therapies on β-Cell Function and Mass |
| Q38053516 | An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: Potential implications in cardiovascular disease |
| Q39679544 | Anti-inflammatory action of exendin-4 in human islets is enhanced by phosphodiesterase inhibitors: potential therapeutic benefits in diabetic patients |
| Q38628366 | Chronic critical illness: the price of survival |
| Q46004687 | Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor restores normoglycaemia in non-obese diabetic mice. |
| Q41094748 | Combined Oral Administration of GABA and DPP-4 Inhibitor Prevents Beta Cell Damage and Promotes Beta Cell Regeneration in Mice |
| Q35288471 | Combining MK626, a novel DPP-4 inhibitor, and low-dose monoclonal CD3 antibody for stable remission of new-onset diabetes in mice |
| Q47370187 | Construction of a novel vaccine by conjugating a B-cell epitope of DPP4 to peptide IA2(5)-P2-1 to significantly control type 1 diabetes in NOD mice |
| Q38284522 | DPP-4 inhibitors: a patent review (2012 - 2014). |
| Q89729129 | Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions |
| Q58448139 | Dipeptidyl peptidase expression during experimental colitis in mice |
| Q37853155 | Dipeptidyl peptidase in autoimmune pathophysiology |
| Q57125138 | Dipeptidyl peptidase-4 inhibitors have adverse effects for the proliferation of human T cells |
| Q38107546 | Dipeptidyl peptidase-4 inhibitors: multitarget drugs, not only antidiabetes drugs. |
| Q90324457 | Dipeptidyl peptidase-4(DPP-4) inhibitors: promising new agents for autoimmune diabetes |
| Q26749226 | Discovery of gastric inhibitory polypeptide and its subsequent fate: Personal reflections |
| Q41873186 | Effect of vildagliptin, a dipeptidyl peptidase 4 inhibitor, on cardiac hypertrophy induced by chronic beta-adrenergic stimulation in rats |
| Q34017323 | Effects of genetic susceptibility for type 2 diabetes on the evolution of glucose homeostasis traits before and after diabetes diagnosis: data from the D.E.S.I.R. Study |
| Q50957731 | Effects of short-term sitagliptin treatment on immune parameters in healthy individuals, a randomized placebo-controlled study. |
| Q86701386 | Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin in an advanced-aged diet-induced obesity mouse model |
| Q100533893 | Evogliptin, a dipeptidyl peptidase-4 inhibitor, attenuates pathological retinal angiogenesis by suppressing vascular endothelial growth factor-induced Arf6 activation |
| Q41846077 | Exenatide Pretreatment Improved Graft Function in Nonhuman Primate Islet Recipients Compared to Treatment after Transplant Only |
| Q37532382 | Four-year clinical remission of type 1 diabetes mellitus in two patients treated with sitagliptin and vitamin D3 |
| Q35285238 | Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. |
| Q30039774 | Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells |
| Q38019105 | Immunotherapies in Diabetes Mellitus Type 1 |
| Q33754087 | Impact of early versus late enteral nutrition on cell mediated immunity and its relationship with glucagon like peptide-1 in intensive care unit patients: a prospective study |
| Q90134815 | Improving the Function and Engraftment of Transplanted Pancreatic Islets Using Pulsed Focused Ultrasound Therapy |
| Q90079848 | Influence of Vitamin D on Islet Autoimmunity and Beta-Cell Function in Type 1 Diabetes |
| Q41205365 | Is There a Role for Bioactive Lipids in the Pathobiology of Diabetes Mellitus? |
| Q91984134 | Past, present and future of latent autoimmune diabetes in adults |
| Q38248682 | Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors |
| Q26798145 | Recent Trends in Therapeutic Approaches for Diabetes Management: A Comprehensive Update |
| Q26778329 | Role of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantation |
| Q38134111 | Role of pancreatic β-cell death and inflammation in diabetes |
| Q40524112 | Saxagliptin improves glycaemic control and C-peptide secretion in latent autoimmune diabetes in adults (LADA). |
| Q33930280 | Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4+ T-cell migration through incretin-dependent and -independent pathways |
| Q50509855 | Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice |
| Q27011453 | Stem cell therapy for diabetes mellitus |
| Q37402021 | Stem cell therapy for type 1 diabetes mellitus: a review of recent clinical trials |
| Q45800033 | The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice |
| Q87135143 | The new insights from DPP-4 inhibitors: their potential immune modulatory function in autoimmune diabetes |
| Q38205588 | The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected]. |
| Q51389658 | Towards PET imaging of intact pancreatic beta cell mass: a transgenic strategy |
| Q44146198 | Treatment of autoimmune diabetes in NOD mice by Toll-like receptor 2 tolerance in conjunction with dipeptidyl peptidase 4 inhibition |
| Q35837580 | Type 1 Diabetes Prevention in NOD Mice by Targeting DPPIV/CD26 Is Associated with Changes in CD8⁺T Effector Memory Subset |
| Q37830198 | Type 1 diabetes: etiology, immunology, and therapeutic strategies |
| Q27013927 | Use of Glucagon-Like Peptide-1 Agonists to Improve Islet Graft Performance |
| Q28081667 | Year in review 2013: Critical Care--metabolism |
Search more.